ArticleHead & neck2025
Outcomes of Reduced Elective Nodal Radiation Dose and Volume for Laryngeal, Hypopharyngeal, and p16-Negative Oropharyngeal Cancers.
Article in Head & neck, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Optimizing the therapeutic ratio: a narrative review of de-escalation and response-adapted strategies in series including human papillomavirus negative head and neck cancer.Translational cancer research · 2026Review
- De-escalation of head-and-neck cancer radiotherapy: balancing cure and side effects.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundReducing elective nodal irradiation dose can decrease treatment toxicity and improve quality of life for head and neck cancer patients.
methodsWe determined the effectiveness of reducing elective radiotherapy doses to 40 Gy for a consecutive cohort of laryngeal, hypopharyngeal, and p16-negative oropharyngeal or unknown primary squamous cell carcinomas treated with concurrent chemoradiation. The primary outcome measure was solitary elective nodal recurrence.
resultsThe cohort included 73 consecutive patients with a median follow up of 23.3 months. There were no cases of solitary elective nodal recurrence. Six patients had locoregional recurrence, eight had distant recurrence, and two had simultaneous locoregional and distant recurrence. All locoregional recurrences occured in the 70 Gy target volume (three in the primary tumor target, three in the involved node target, and two in both).
conclusionsReduction in elective nodal radiation dose did not lead to solitary elective nodal recurrences for laryngeal, hypopharyngeal, and p16-negative oropharyngeal cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.